Alternative approaches to conventional treatment of acute uncomplicated urinary tract infection in women

Current Infectious Disease Reports

Volumn 15, Issue 2, 2013, Pages 124-129

  Foxman, Betsy ^a   Buxton, Miatta ^a  

^a UNIVERSITY OF MICHIGAN SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Antiinflammatories; Functional foods; Probiotics; Vaccines

Indexed keywords

AMOXICILLIN; ANTIBIOTIC AGENT; BACTERIAL VACCINE; CIPROFLOXACIN; COTRIMOXAZOLE; IBUPROFEN; IROMUNE; NATURAL PRODUCT; NITROFURANTOIN; OM 89; PLACEBO; PROBIOTIC AGENT; SULFAMETHOXAZOLE; TRIMETHOPRIM; UNCLASSIFIED DRUG; UROVAXOM;

ALTERNATIVE MEDICINE; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; BACTERIOPHAGE; CRANBERRY; ESCHERICHIA COLI; FEMALE; FOOD; HERBAL MEDICINE; HORSERADISH; HUMAN; LACTOBACILLUS; LACTOBACILLUS CRISPATUS; LACTOBACILLUS REUTERI; LACTOBACILLUS RHAMNOSUS; NASTURTIUM; NONHUMAN; RECURRENT INFECTION; RICE; SALVIA; SALVIA PLEBEIA; URINARY TRACT INFECTION;

EID: 84877921469     PISSN: 15233847     EISSN: 15343146     Source Type: Journal    
DOI: 10.1007/s11908-013-0317-5     Document Type: Article

References (58)

1. Foxman B, Brown P. Epidemiology of urinary tract infections: transmission and risk factors, incidence, and costs. Infect Dis Clin North Am. 2003;17:227-41.
2. Naber KG, Wullt B, Wagenlehner FM. Antibiotic treatment of uncomplicated urinary tract infection in premenopausal women. Int J Antimicrob Agents. 2011;38:21-35.
3. Ellis AK, Verma S. Quality of life in women with urinary tract infections: is benign disease a misnomer. J Am Board Fam Pract. 2002;13:392-7.
4. Arinzon Z, Shabat S, Peisakh A, Berner Y. Clinical presentation of urinary tract infection (UTI) differs with aging in women. Arch Gerontol Geriatr. 2012;55:145-7.
5. Hooton TM. Uncomplicated urinary tract infection. N Engl J Med. 2012;366:1028-37. Case vignette and review of treatment of uncomplicated urinary tract infection.
6. Coque TM, Baquero F, Cantón R. Increasing prevalence of ESBL-producing Enterobacteriaceae in Europe. Euro Surveill. 2008;13(47). pii: 19044.
7. Meier S, Weber R, Zbinden R, Ruef C, Hasse B. Extended-spectrum β-lactamase-producing Gram-negative pathogens in community-acquired urinary tract infections: an increasing challenge for antimicrobial therapy. Infection. 2011;39:333-40. Retrospective study comparing community-acquired and healthcare-associated urinary tract infections due to ESBL-producing E. coli.
8. Fennell J, Vellinga A, Hanahoe B, Morris D, Boyle F, Higgins F, et al. Increasing prevalence of ESBL production among Irish clinical Enterobacteriaceae from 2004 to 2008: an observational study. BMC Infect Dis. 2012;12:116.
9. Dethlefsen L, Huse S, Sogin ML, Relman DA. The pervasive effects of an antibiotic on the human gut microbiota, as revealed by deep 16S rRNA sequencing. PLoS Biol. 2008;6:e280.
10. Gibreel TM, Dodgson AR, Cheesbrough J, Fox AJ, Bolton FJ, Upton M. Population structure, virulence potential and antibiotic susceptibility of uropathogenic Escherichia coli from northwest England. J Antimicrob Chemother. 2012;67:346-56. Phylogenetic analysis and virulence gene characterization of 300 uropathogenic E. coli.
11. Oteo J, Perez-Vazquez M, Campos J. Extended-spectrum [beta]-lactamase producing Escherichia coli: changing epidemiology and clinical impact. Curr Opin Infect Dis. 2010;23:320-6.
12. Chan HL, Stern RS, Arndt KA, Langlois J, Jick SS, Jick H, et al. The incidence of erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis. A population-based study with particular reference to reactions caused by drugs among outpatients. Arch Dermatol. 1990;126(1):43-7.
13. CIPRO® (ciprofloxacin hydrochloride) tablets, CIPRO® (ciprofloxacin*) oral SUSPENSION [Internet]. Available from: http://www.fda.gov/downloads/Drugs/EmergencyPreparedness/ BioterrorismandDrugPreparedness/UCM130802.pdf.
14. Mehlhorn AJ, Brown DA. Safety concerns with fluoroquinolones. Ann Pharmacother. 2007;41:1859-66.
15. Walbrown MA, Aspinall SL, Bayliss NK, Stone RA, Cunningham F, Squier CL, et al. Evaluation of Clostridium difficile-associated diarrhea with a drug formulary change in preferred fluoroquinolones. J Manag Care Pharm. 2008;14:34-40.
16. Xu J, Schwartz K, Bartoces M, Monsur J, Severson RK, Sobel JD. Effect of antibiotics on vulvovaginal candidiasis: a MetroNet study. J Am Board Fam Med. 2008;21:261-8.
17. Schmiemann G, Kniehl E, Gebhardt K, Matejczyk MM, Hummers-Pradier E. The diagnosis of urinary tract infection: a systematic review. Dtsch Arztebl Int. 2010;107:361-7.
18. Su SB, Wang JN, Lu CW, Guo HR. Reducing urinary tract infections among female clean room workers. J Womens Health (Larchmt). 2006;15:870-6.
19. Arya LA, Northington GM, Asfaw T, Harvie H, Malykhina A. Evidence of bladder oversensitivity in the absence of an infection in premenopausal women with a history of recurrent urinary tract infections. BJU Int. 2012;110:247-51.
20. Rozin A, Schapira D, Braun-Moscovici Y, Nahir A. Cotrimoxazole treatment for rheumatoid arthritis. Semin Arthritis Rheum. 2001;31:133-41.
21. Bleidorn J, Gagyor I, Kochen MM, Wegscheider K, Hummers-Pradier E. Symptomatic treatment (ibuprofen) or antibiotics (ciprofloxacin) for uncomplicated urinary tract infection? -Results of a randomized controlled pilot trial. BMC Med. 2010;8:30. Pilot trial comparing ciprofloxacin to ibuprofen suggesting noninferiority.
22. Christiaens TC, De Meyere M, Verschraegen G, Peersman W, Heytens S, De Maeseneer JM. Randomised controlled trial of nitrofurantoin versus placebo in the treatment of uncomplicated urinary tract infection in adult women. Br J Gen Pract. 2002;52:729-34.
23. Ferry SA, Holm SE, Stenlund H, Lundholm R, Monsen TJ. The natural course of uncomplicated lower urinary tract infection in women illustrated by a randomized placebo controlled study. Scand J Infect Dis. 2004;36:296-301.
24. Katchman EA, Milo G, Paul M, Christiaaens T, Baerheim A, Leibovici L. Three-day vs longer duration of antibiotic treatment for cystitis in women: systematic review and meta-analysis. Am J Med. 2005;118:1196-207.
25. Foxman B, Gillespie B, Koopman J, Zhang L, Palin K, Tallman P, et al. Risk factors for second urinary tract infection among college women. Am J Epidemiol. 2000;151:1194-205.
26. Brumbaugh AR, Mobley HL. Preventing urinary tract infection: progress toward an effective Escherichia coli vaccine. Expert Rev Vaccines. 2012;11:663-76. Recent comprehensive review of UTI vaccines.
27. Jepson RG, Williams G, Craig JC. Cranberries for preventing urinary tract infections. Cochrane Database Syst Rev. 2012;10:CD001321. doi: 10.1002/14651858.CD001321.pub5. Metaanalysis of randomized controlled trials assessing cranberry effectiveness in UTI treatment.
28. Harjai K, Kumar R, Singh S. Garlic blocks quorum sensing and attenuates the virulence of Pseudomonas aeruginosa. FEMS Immunol Med Microbiol. 2010;58:161-8.
29. Albrecht U, Goos KH, Schneider B. A randomised, double-blind, placebo-controlled trial of a herbal medicinal product containing Tropaeoli majoris her-ba (Nasturtium) and Armoraciae rusticanae radix (Horseradish) for the prophylactic treatment of patients with chronically recurrent lower urinary tract infections. Curr Med Res Opin. 2007;23:2415-22.
30. Chung YC, Chen HH, Yeh ML. Vinegar for decreasing catheter-associated bacteriuria in long-term catheterized patients: a randomized controlled trial. Biol Res Nurs. 2012;14:294-301.
31. Peng MM, Fang Y, Hu W, Huang Q. The pharmacological activities of Compound Salvia Plebeia Granules on treating urinary tract infection. J Ethnopharmacol. 2010;129:59-63.
32. Foxman B, Manning S, Tallman P, Bauer R, Zhang L, Koopman J, et al. Uropathogenic Escherichia coli are more likely than commensal E. coli to be shared between heterosexual sex partners. Am J Epidemiol. 2002;158:1133-40.
33. Schlager TA, Ashe KM, Hendley JO. The ability of periurethral Escherichia coli to grow in a voiding system is a key for the dominance of E. coli cystitis. Microb Pathog. 1997;22:235-40.
34. Xie J, Foxman B, Zhang L, Marrs CF. Molecular epidemiologic identification of Escherichia coli genes that are potentially involved in movement of organisms from intestinal tract to the vagina and bladder. J Clin Microbiol. 2006;44:2434-41.
35. Karlsson M, Scherbak N, Khalaf H, Olsson PE, Jass J. Substances released from probiotic Lactobacillus rhamnosus GR-1 potentiate NF-κB activity in Escherichia coli-simulated urinary bladder cells. FEMS Immunol Med Microbiol. 2012;66:147-56.
36. Stapleton AE, Au-Yeung M, Hooton TM, Fredricks DN, Roberts PL, Czaja CA, et al. Randomized, placebo-controlled phase 2 trial of a Lactobacillus crispatus probiotic given intravaginally for prevention of recurrent urinary tract infection. Clin Infect Dis. 2011;52:1212-7.
37. Beereport MA, ter Riet G, Nys S, van der Wal WM, de Borgie CA, de Reijke TM, et al. Lactobacilli vs antibiotics to prevent urinary tract infections: a randomized, double blind, noninferiority trial in postmenopausal women. Arch Intern Med. 2012;172:704-12.
38. Trautner B.W., Gupta K., The advantages of second best: Comment on «lactobacilli vs antibiotics to prevent urinary tract infections» (2012), Arch Intern Med, 172, 712-714.
39. Swidsinski A, Loening-Baucke V, Mendling W, Swidsinski S. Positive effects of local therapy with a vaginal lactic acid gel on dysuria and E. coli bacteriuria question our current views on recurrent cystitis. Arch Gynecol Obstet. 2012;285:1619-25.
40. Lorenzo-Gomez MF, Padilla-Fernandez B, Garcia-Criado FJ, Miron-Canelo JA, Gil-Vicente A, Nieto-Huertos A, et al. Evaluation of a therapeutic vaccine for the prevention of recurrent urinary tract infections versus prophylactic treatment with antibiotics. Int Urogynecol J. 2013;24:127-34.
41. Bauer HW, Alloussi S, Egger G, Blumlein HM, Cozma G, Schulman CC. A long-term, multicenter, double-blind study of an Escherichia coli extract (OM-89) in female patients with recurrent urinary tract infections. Eur Urol. 2005;47:542-8.
42. Cai T, Mazzoli S, Mondaini N, Meacci F, Nesi G, D'Elia C, et al. The role of asymptomatic bacteriuria in young women with recurrent urinary tract infections: to treat or not to treat? Clin Infect Dis. 2012;55:771-7. Trial demonstrating increased risk of symptomatic UTI among women with asymptomatic bacteriuria treated with antibiotics.
43. Hansson S, Jodal U, Lincoln K, Svanborg-Eden C. Untreated asymptomatic bacteriuria in girls: II - Effect of phenoxymethylpenicillin and erythromycin given for intercurrent infections. BMJ. 1989;298:856-9.
44. Sundén F, Håkansson L, Ljunggren E, Wullt B. Escherichia coli 83972 bacteriuria protects against recurrent lower urinary tract infections in patients with incomplete bladder emptying. J Urol. 2010;184:179-85.
45. Hernandez JG, Sunden F, Connolly J, Svanborg C, Wullt B. Genetic control of the variable innate Immune response to asymptomatic bacteriuria. PLoS One. 2011;6:e28289.
46. Chibeu AA, Lingohr EJE, Masson LL, Manges AA, Harel JJ, Ackermann HW, et al. Bacteriophages with the ability to degrade uropathogenic Escherichia coli biofilms. Viruses. 2012;4:471-87.
47. Housby JN, Mann NH. Phage therapy. Drug Discovery Today. 2009;14:536-40.
48. Gagyor I, Hummers-Pradier E, Kochen MM, Schmiemann G, Wegscheider K, Bleidorn J. Immediate versus conditional treatment of uncomplicated urinary tract infection - a randomized-controlled comparative effectiveness study in general practices. BMC Infect Dis. 2012;12:146.
49. Baerheim A. Empirical treatment of uncomplicated cystitis. Scand J Prim Health Care. 2012;30:1-2.
50. eMedExpert. Available from: http://www.emedexpert.com.
51. Huovinen P, Sundström L, Swedberg G, Sköld O. Trimethoprim and sulfonamide resistance. Antimicrob Agents Chemother. 1995;39:279-89.
52. Eliopoulos G, Huovinen P. Resistance to trimethoprim sulfamethoxazole. Clin Infect Dis. 2001;32:1608-14.
53. Skold O. Sulfonamide resistance: mechanisms and trends. Drug Resist Updat. 2000;3:155-60.
54. Mylan Pharmaceuticals. Morgantown, WV. Available from: http://dailymed.nlm.nih.gov/dailymed/archives/fdaDrugInfo.cfm?archiveid=2718.
55. Thomson CJ. The global epidemiology of resistance to ciprofloxacin and the changing nature of antibiotic resistance: a 10 year perspective. J Antimicrob Chemother. 1999;43:31-40.
56. Mossialos E, Morel CM, Edwards S, Berenson J, Gemmill-Toyama M, Brogan D. Policies and incentives for promoting innovation in antibiotic research. European Observatory on Health Systems and Policies. Available from: http://www.euro.who.int/-data/assets/pdf-file/0011/120143/E94241.pdf.
57. Bannatyne RM, Toma S, Cheung R, Hu G, Taylor D, Keystone JS, et al. Resistance to trimethoprim and other antibiotics in Ontario Shigellæ. Lancet. 1980;315:425-26.
58. Kass EH. Chemotherapeutic and antibiotic drugs in the management of infections of the urinary tract. Am J Med. 1955;18:764-81.